Evidence map›Paper›PMID 40932546›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Dammarolic acid improves tyrosine kinase inhibitor activity in lung cancer cells.

Yusuf Hussain, Jyoti Singh, Abha Meena, Rohit Anthony Sinha, Suaib Luqman

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yusuf HussainBioprospection and Product Development Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Uttar Pradesh, Lucknow, 226015, India.
Jyoti SinghBioprospection and Product Development Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Uttar Pradesh, Lucknow, 226015, India.
Abha MeenaBioprospection and Product Development Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Uttar Pradesh, Lucknow, 226015, India. ameena.cimap@csir.res.in.
Rohit Anthony SinhaDepartment of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Uttar Pradesh, Lucknow, 226014, India.
Suaib LuqmanBioprospection and Product Development Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Uttar Pradesh, Lucknow, 226015, India.

Funding

CSIR-CIMAP HCP-007
6 · The paper itself

Abstract

Lung cancer is a leading global health concern, ranking as the second-highest cause of cancer-related deaths. Tyrosine kinase inhibitors (TKIs) such sorafenib or regorafenib are considered the second-line drugs to treat advanced lung cancer. At advanced stages of lung cancer, the efficacy of TKIs gets reduced and does not produce prolonged effects. Thus, there is a need to discover new ways to increase the efficacy of TKIs for better outcomes. In the present study, synergistic approaches are utilized to improve the anticancer activity of TKIs. We investigated the synergisitic potential of dammarolic acid (DA) with sorafenib in lung cancer cell lines. DA, a triterpenoid derived from Centella asiatica, has demonstrated various medicinal properties. This study explores the combined effects of DA and sorafenib on lung cancer cells focusing on their synergistic mechanisms. To assess this synergy, the half-maximal inhibitory concentration (IC

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsLung NeoplasmsProtein Kinase InhibitorsSorafenibTriterpenesApoptosisAutophagyCell Line, TumorCell ProliferationDrug SynergismHumansMembrane Potential, MitochondrialReactive Oxygen SpeciesTyrosine Kinase InhibitorsAntineoplastic AgentsProtein Kinase InhibitorsReactive Oxygen SpeciesSorafenibTriterpenesTyrosine Kinase InhibitorsAutophagy, Dammarolic acidCentella asiaticaLung cancerSorafenibSynergy

Identifiers

PMID40932546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.